Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 55

1.

The prevalence and pathogenesis of diabetes mellitus in treated HIV-infection.

Paik IJ, Kotler DP.

Best Pract Res Clin Endocrinol Metab. 2011 Jun;25(3):469-78. doi: 10.1016/j.beem.2011.04.003. Review.

PMID:
21663840
2.

Prevalence and pathogenesis of diabetes mellitus in HIV-1 infection treated with combined antiretroviral therapy.

Samaras K.

J Acquir Immune Defic Syndr. 2009 Apr 15;50(5):499-505. doi: 10.1097/QAI.0b013e31819c291b. Review.

PMID:
19223782
3.

Insulin resistance, glucose intolerance and diabetes mellitus in HIV-infected patients.

Florescu D, Kotler DP.

Antivir Ther. 2007;12(2):149-62. Review.

PMID:
17503657
4.

Disorders of glucose metabolism in patients infected with human immunodeficiency virus.

Dubé MP.

Clin Infect Dis. 2000 Dec;31(6):1467-75. Epub 2000 Nov 29. Review.

PMID:
11096014
5.

Metabolic complications associated with antiretroviral therapy.

Jain RG, Furfine ES, Pedneault L, White AJ, Lenhard JM.

Antiviral Res. 2001 Sep;51(3):151-77. Review.

PMID:
11448728
6.

Lipid metabolism in treated HIV Infection.

Dubé MP, Cadden JJ.

Best Pract Res Clin Endocrinol Metab. 2011 Jun;25(3):429-42. doi: 10.1016/j.beem.2011.04.004. Review.

PMID:
21663837
7.

New-onset diabetes mellitus associated with protease inhibitor therapy in an HIV-positive patient: case report and review.

Lee EC, Walmsley S, Fantus IG.

CMAJ. 1999 Jul 27;161(2):161-4. Review. No abstract available.

8.

Adipocytes targets and actors in the pathogenesis of HIV-associated lipodystrophy and metabolic alterations.

Gougeon ML, Pénicaud L, Fromenty B, Leclercq P, Viard JP, Capeau J.

Antivir Ther. 2004 Apr;9(2):161-77. Review.

PMID:
15134178
9.

Adverse metabolic disorders during highly active antiretroviral treatments (HAART) of HIV disease.

Vigouroux C, Gharakhanian S, Salhi Y, Nguyên TH, Adda N, Rozenbaum W, Capeau J.

Diabetes Metab. 1999 Nov;25(5):383-92. Review.

PMID:
10592860
10.

Cutaneous toxicities of antiretroviral therapy for HIV: part I. Lipodystrophy syndrome, nucleoside reverse transcriptase inhibitors, and protease inhibitors.

Introcaso CE, Hines JM, Kovarik CL.

J Am Acad Dermatol. 2010 Oct;63(4):549-61; quiz 561-2. doi: 10.1016/j.jaad.2010.01.061. Review.

PMID:
20846563
11.

Getting to the HAART of insulin resistance.

Nolan D, Mallal S.

AIDS. 2001 Oct 19;15(15):2037-41. Review. No abstract available.

PMID:
11600834
12.

Antiretroviral therapy and the human immunodeficiency virus--improved survival but at what cost?

Bradbury RA, Samaras K.

Diabetes Obes Metab. 2008 Jun;10(6):441-50. Epub 2007 Sep 6. Review.

PMID:
17825081
13.

Management of the adverse effects of antiretroviral therapy and medication adherence.

Max B, Sherer R.

Clin Infect Dis. 2000 Jun;30 Suppl 2:S96-116. Review.

PMID:
10860894
14.

HIV-associated lipodystrophy syndrome.

Qaqish RB, Fisher E, Rublein J, Wohl DA.

Pharmacotherapy. 2000 Jan;20(1):13-22. Review.

PMID:
10641972
15.

Current treatment strategies, complications and considerations for the use of HIV antiretroviral therapy during pregnancy.

Senise JF, Castelo A, Martínez M.

AIDS Rev. 2011 Oct-Dec;13(4):198-213. Review.

PMID:
21975356
16.

Sex differences in adverse reactions to antiretroviral drugs.

Ofotokun I, Pomeroy C.

Top HIV Med. 2003 Mar-Apr;11(2):55-9. Review.

17.

Tolerability and safety of HIV protease inhibitors in adults.

Sax PE, Kumar P.

J Acquir Immune Defic Syndr. 2004 Sep 1;37(1):1111-24. Review. Erratum in: J Acquir Immune Defic Syndr. 2004 Nov 1;37(3):1434.

PMID:
15319670
18.

Neurologic and psychiatric complications of antiretroviral agents.

Treisman GJ, Kaplin AI.

AIDS. 2002 Jun 14;16(9):1201-15. Review. No abstract available.

PMID:
12045485
19.

Insulin resistance in treated HIV infection.

Feeney ER, Mallon PW.

Best Pract Res Clin Endocrinol Metab. 2011 Jun;25(3):443-58. doi: 10.1016/j.beem.2010.11.002. Review.

PMID:
21663838
20.

Supplemental Content

Support Center